Sanofi recalls arthritis injection that is tied to microbial contamination

Sanofi is recalling nearly 13,000 Synvisc One syringes used to treat arthritis that come from a lot that tested positive for microbial contamination.

Sanofi has initiated a U.S. recall of a lot of its injected gel for treating arthritis in knees which has tested positive for microbial contamination and been linked to some adverse events.

Sanofi spokeswoman Ashleigh Koss confirmed today that the company is voluntarily recalling 12,380 syringes of Synvisc One in conjunction with the FDA that may be contaminated. They were produced by its Genzyme unit at a plant in Ridgefield, New Jersey.

Genzyme is based in Cambridge, Massachusetts. The recall was first reported in the Boston Globe.

Webinar

Innovative and Flexible Solutions for an End-to-End Patient-Centric, Lean Supply Chain

The trend toward crafting patient-centric clinical trials hold great promise in supporting patients’ willingness and ability to participate in important clinical research. This webinar will explore how recent innovations in forecasting, supply pooling, decentralized processing, labeling, demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric.

Sanofi put a hold on the lot last week after getting a surge of adverse event reports. Koss said the adverse events have been consistent with the product labeling and there have been no deaths.  

In a letter to providers the company said, "This is a voluntary product recall due to an ongoing investigation in which subsequent investigational testing revealed the presence of microbial contamination. ....Use of this recalled lot may result in a risk of infection and therefore, we are asking that you follow the required actions below to assist us in retrieving any remaining units of this voluntarily recalled lot."

Synvisc One, which was approved by the FDA in 2009, generated nearly $410 million in sales last year. The lubricant and shock-absorbing gel is injected into the knee to provide up to 6 months' worth of relief for people with arthritis of the knee.

RELATED: Sanofi and Regeneron's expected blockbuster hit with FDA CRL for manufacturing concerns

About this time last year, the French drugmaker ran into problems at a plant in France that produced another injected arthritis med. In that case, a long list of deficiencies at the fill-finish plant in Le Trait, France, led the FDA to issue a complete response letter to Sanofi and partner Regeneron for experimental rheumatoid arthritis drug, and expected blockbuster, sarilumab. After more than 6 months of work on the plant, the FDA finally approved the drug, sold as Kevzara.

Suggested Articles

Here is some more manufacturing news from the week.

Lyophilization Services of New England already has four facilities in the U.S. but has now jumped the Atlantic to pick up its first location in Europe.

Boehringer Ingelheim has invested €225 million on inhaler production with a new plant in Spain and expanded lines in Germany.